Introduction
============

Deep brain stimulation of the subthalamic nucleus (DBS-STN) is an established surgical treatment for motor fluctuations or dyskinesia in Parkinson\'s disease (PD).[@b1]--[@b3] The outcome critically depends on appropriate lead location[@b4] and setting of stimulation parameters. Inadvertent leakage of current into adjacent fiber tracts, such as pyramidal fibers lateral to the STN,[@b5] limits the therapeutic window (TW) by causing dysarthria or impaired fine motor skills.[@b6] As a result, much research has been devoted to modeling and visualizing the electrical field of a given electrode position and parameter setting within the individual brain anatomy[@b7] and to developing new stimulation hardware allowing more flexible shaping of the current distribution.[@b8]

Stimulation effects, however, also depend on the temporal characteristics of the stimulus waveform. The threshold for activation of neural elements with different membrane excitability properties covaries with stimulus strength, and duration of the stimulus pulse. The nonlinear interdependance of stimulus amplitude and pulse duration is reflected by the so called "strength--duration-curve" or chronaxie relationship. The minimal amount of current necessary to excite a neural element at an infinitely long pulse width (PW) is termed rheobase current. Chronaxie is a measure of the excitability of neural elements and has been defined as the pulse duration equivalent to the double rheobase current on the strength--duration curve.

Experimental measurements have documented that axons have lower chronaxies than neuron cell bodies.[@b9] Chronaxies for the beneficial effects of DBS have been estimated to be around 129 *μ*sec for thalamic and around 151 *μ*sec for pallidal stimulation[@b10],[@b11] which is well within the range of myelinated axons. Here, we present chronaxie evaluations of STN-DBS using a novel neurostimulation system (Vercise®; Boston Scientific, Valencia, CA). In particular, we explored the clinical usefulness of stimulation at ultra-short pulse duration as physiological concepts suggest that stimulation at PW \<60 *μ*sec could improve the selectivity of DBS for particular neural elements and lead to a better distinction between desirable and adverse stimulation effects.

Subjects and Methods
====================

Four patients (two female, age 49--62 years), who had been implanted with the Vercise® neurostimulation system (Boston Scientific, Valencia, CA) for bilateral DBS-STN in PD, underwent an extended programming session of their DBS system in the practically defined medication off-state (\>12 h medication withdrawal) 2--4 months after surgery. Patients were included into the extended monopolar review session for optimizing their stimulation parameters after having had a stable clinical response to STN-DBS of greater than 30% motor score reduction with conventional programming parameters for at least 1 month. Goal of the monopolar review session was to determine the clinically optimal pulse duration and amplitude setting at the monopolar contact previously selected for chronic stimulation at 60 *μ*sec PW. Efficacy of neurostimulation was assessed by comparing the severity of motor symptoms at the begin of the review session ON DBS to the preoperative Unified Parkinson\'s Disease Rating Scale, part III (UPDRS-III) in the medication off-state.

In all patients\' correct lead positioning had been verified by fusing the preoperative stereotactic MRI and chronic (≥40 days) postoperative CT using the stereotactic planning software (Leksell SurgiPlan, Elekta, Sweden). The mean AC-PC based coordinates of active contacts of the right hemisphere were 12.1 ± 0.8 mm lateral to AC-PC 2.14 ± 1.37 mm below AC-PC, 1.62 ± 0.7 mm posterior to MCP, and of left hemispheric active contacts 13.4 ± 0.59 mm lateral, 2.9 ± 1.3 mm below and 1.4 ± 0.8 mm posterior.

For the monopolar review session we defined the efficacy threshold of DBS as the minimal current necessary to achieve complete or almost complete suppression of contralateral rigidity (corresponding to a UPDRS item 22 score of 0 or 1) and the adverse effect threshold as the minimal current inducing clinically noticeable side effects (e.g., muscle contraction). In random order we assessed the TW for the pulse durations 20, 30, 40, 50, 60, 90, and 120 *μ*sec at a frequency of 130 Hz by quickly ramping up current until adverse effects were noted and carefully titrating the current to determine the exact threshold. Thereafter, current was lowered until contralateral arm rigidity returned to baseline severity (efficacy threshold). If no adverse effect could be encountered after increasing amplitude to 10 mA, testing was suspended and no TW could be determined. TW (in mA) was calculated for each tested PW by subtracting the efficacy threshold from the side effect threshold. For comparison between subjects TWs were normalized to the TW at 60 *μ*sec.

We calculated the chronaxies from the threshold currents for suppression of rigidity and muscle contractions by linearizing the strength--duration curves and estimating slope and intercept.[@b12]

Computational model of axonal activation
----------------------------------------

An idealized DBS model was constructed to assist in the interpretation of the clinical results. The model system consisted of a finite element electric field model of the DBS electrode, coupled to populations of multicompartment cable models of myelinated axons. Our previous work described the specific parameters of the electric field model[@b13] and axon models.[@b14] The effects of the DBS electric field on the axons were simulated using methods originally described by McNeal,[@b15] adapted to specifically address modulation of the DBS waveform.[@b16] Our simulations evaluated DBS of two distinct pathways near the DBS electrode. One pathway consisted of smaller (2 *μ*m) diameter axons located closer (1--2 mm) the electrode, while the other pathway consisted of larger (5.7 *μ*m) diameter axons located farther from (4--5 mm) the electrode. The threshold current for action potential initiation was calculated for each axon model in each pathway, as a function of the PW.

Results
=======

The patients had a mean UPDRS-III motor score improvement from 51 ± 11.97 before surgery to 24.75 ± 8.58 points (−52%) in the medication off-state with STN-DBS.

During the monopolar review session we observed a clear inverse relationship between PW and side effect thresholds in all patients. Mild contractions or fasciculations in hand or face muscles were elicited in all cases and served to determine the threshold for activation of pyramidal tract fibers. We did not notice other stimulation induced adverse effects below this threshold in any patient. Complete determination of TW was possible for seven implanted electrodes due to a lack of testable rigidity contralateral to one. The TW was 2.2 ± 1.6 mA (median 2.3; range 3.9) at 60 *μ*sec, which proportionally increased by 182 ± 128% (median 160%; range 341%) at 30 *μ*sec, while decreasing by 46 ± 28% (median 34%; range 84%) at 120 *μ*sec (Fig.[1](#fig01){ref-type="fig"}). At 20 *μ*sec PW assessment of the TW was unreliable, because we could not elicit a capsular response for 6/8 electrodes below our testing limit of 10 mA.

![(A) linearized strength--duration curves for rigidity control and muscle contractions. (B) Bar graph depicting the relative change in therapeutic window compared to 60 *μ*sec pulse duration (TW~60 *μ*sec~). Error bars indicate the standard error of mean in both graphs.](acn30002-0427-f1){#fig01}

The threshold current for complete rigidity control increased from 1.6 ± 0.9 (median 1.5; range 2.4) mA at 60 *μ*sec to 2.9 ± 1.4 (median 2.8; range 3.6) mA at 30 *μ*sec but the calculated total charge delivered per pulse was actually lower: 95 ± 51 (median 90; range 14) nC/pulse at 60 *μ*sec versus 88 ± 43 (median 84; range 108) nC/pulse at 30 *μ*sec; −7%).

For both strength--duration curves we found a significant linear regression fit (rigidity control: *r* = 0.97; contractions: 0.94), when plotting mean threshold amplitudes against the inverse of pulse duration (Fig.[2](#fig02){ref-type="fig"}). The slopes of the two regression lines were significantly divergent (74.8 ± 5.8 vs. 168.4 ± 19.0; *P* \< 0.0001) indicating the stimulation of neural elements with different membrane excitability. From the mean and confidence range of the slopes we determined a chronaxie of 225 *μ*sec (95% confidence range: 180--270 *μ*sec) for the suppression of rigidity and 126 *μ*sec (95% confidence range: 90--163 *μ*sec) for muscular contractions.

![Model derived strength--duration curves for action potential initiation in smaller (2 *μ*m) diameter axons located closer (1--2 mm) the electrode as compared to larger (5.7 *μ*m) diameter axons located farther from (4--5 mm) the electrode. At shorter pulse duration the two curves diverge explaining an increased "therapeutic window" if benefit was associated with stimulation of the nearby fibers and adverse effects with the distant thick myeliniated axons.](acn30002-0427-f2){#fig02}

Discussion
==========

This is the first systematic analysis of the impact of pulse duration on therapeutic and adverse effects of subthalamic deep brain stimulation.

We found, that the TW of subthalamic neurostimulation increased up to twofold when using an ultra-short PW of 30 *μ*sec compared to the standard PW setting of 60 *μ*sec, currently suggested for STN-DBS programming.[@b6] At 20 *μ*sec pulse duration we could not elicit any capsular response below our upper testing limit of 10 mA in 6/8 electrodes suggesting an even better benefit/risk ratio. As expected, the efficacy threshold in mA increased at shorter pulse durations, but the total charge per pulse required for full rigidity control did actually decrease, suggesting that short PW stimulation may not only offer less risk of inducing stimulation induced adverse effects but also improve the energy efficiency of DBS. This would result in greater longevity of primary cell devices or expanded charging cycles of rechargeable pulse generators.

The estimated chronaxie of 168 *μ*sec for muscle contraction is well below the limit of \<200 *μ*sec for fast conducting pyramidal tract fibers, whereas a chronaxie of 222 *μ*sec for rigidity suppression indicates stimulation of smaller axons with values between 200 and 700 *μ*sec.[@b9] In order to assist in the interpretation of these clinical results, we devised a computational model consisting of a finite element electric field model of the DBS electrode, coupled to populations of multicompartment cable models of myelinated axons.[@b17],[@b18] The effects of the DBS electric field on the axons were simulated using methods originally described by McNeal,[@b15] adapted to specifically address modulation of the DBS waveform.[@b16] In keeping with the chronaxie data, our simulations evaluated DBS of smaller (2 *μ*m) diameter axons located closer (1--2 mm) and larger (5.7 *μ*m) diameter axons located farther (4--5 mm) from the electrode corresponding to the approximate distance of the pyramidal tract. The current thresholds for generating a propagating axon potential predicted by the model reproduced the marked increase in TW at pulse durations below 60 *μ*sec (Table[1](#tbl1){ref-type="table"}). Hence, the mechanism of stimulation at short pulse duration may be best explained by focusing on excitation of smaller myelinated axons near the electrode and a steeper falloff for activation of thick myelinated axons with increasing radius of current spread.

###### 

Measured and model estimated threshold amplitudes for rigidity control and muscle contractions (capsular response) at different pulse durations

  Pulse width (*μ*sec)   Threshold amplitude (mA)                               
  ---------------------- -------------------------- ------------- ------------- --------------
  20                     3.88 ± 2.03                9.05 ± 0.78   7.75 ± 1.99   10.85 ± 1.17
  30                     2.94 ± 1.43                7.94 ± 1.30   6.03 ± 1.55   8.43 ± 0.91
  40                     2.39 ± 1.17                6.14 ± 0.93   4.96 ± 1.27   6.94 ± 0.74
  50                     1.98 ± 0.98                4.53 ± 1.25   4.23 ± 1.08   5.92 ± 0.63
  60                     1.59 ± 0.86                3.74 ± 0.92   3.7 ± 0.94    5.18 ± 0.55
  70                     --                         --            3.29 ± 0.84   4.61 ± 0.49
  80                     --                         --            2.98 ± 0.76   4.17 ± 0.44
  90                     1.21 ± 0.71                2.94 ± 0.68   2.72 ± 0.69   3.81 ± 0.40
  100                    --                         --            2.5 ± 0.64    3.52 ± 0.37
  110                    --                         --            2.33 ± 0.59   3.27 ± 0.35
  120                    0.63 ± 0.40                2.60 ± 0.89   2.17 ± 0.55   3.06 ± 0.32

Values are given as mean ± SD.

Our chronaxie measurements do not allow us to explicitly determine the anatomical nature of the fibers responsible for rigidity control. The chronaxie could represent excitation of a single fiber pathway or a mixed effect of multiple fibers in the subthalamic area, such as corticosubthalamic fibers, pallidothalamic fibers dorsal to the STN or pallidosubthalamic fibers crossing the internal capsule. Rodent models, however, suggest antidromic driving of corticosubthalamic fibers ("hyperdirect pathway") and subsequent retuning of motor cortical spike firing as critical for the antiparkinsonian effect of subthalamic neurostimulation.[@b19],[@b20] In the rat the hyperdirect pathway consists of thin collaterals of fast conducting pyramidal tract axons originating from the frontal cortex deep layer V neurons.[@b21] First imaging studies in humans did indeed visualize the "hyperdirect" pathway as a small bundle traveling along the internal capsule with the highest connectivity in the dorsolateral portion of the STN.[@b22] Hence, programming in STN-DBS could face the dilemma of needing some current spread into the internal capsule for optimal coverage of those pyramidal tract collaterals, while at the same time avoiding inadvertent stimulation of adjacent corticospinal and corticobulbar fibers.

Our data suggest that this may be best achieved by stimulating at pulse durations below 60 *μ*sec. A limitation may be the small number of patients investigated. However, the results were consistent and the strength--duration relation is a well-known physiological phenomenon, which was only reproduced in this study. Variability in our measures could result from the unblinded clinical assessments, but neither rigidity nor fibrillations or contractions as a result of capsular stimulation can be reliably detected using objective methods.

A future clinical study including blinded assessments of stimulation effects on all Parkinsonian symptoms needs to ascertain this concept.
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